LexaGene’s MiQLab™ genetic analyzer offers rapid automated pathogen detection and customized testing to multi-billion dollar markets.
Human Clinical Diagnostics
- COVID-19 testing $5.2 Billion USD market
- Rapid point-of-need testing
- Multiplex and sensitive
Veterinary Diagnostics
$2.2 billion USD Market by 2024
- Companion animal diagnostics
- Infections and antibiotic resistance can be quickly detected so the appropriate antibiotic is prescribed
- Reference laboratory accounts for largest market share of the veterinary diagnostics market
- North America accounts for largest segment due to well-established animal healthcare market
Food Safety
$23.4 Billion USD market by 2024
- 1.1 B tests performed per year
- Mandatory food testing now required
- Prevents costly recalls, brand damage
- Fresher, safer product to customer (eliminates 2-day hold on food)
- Hundreds of food recalls in the US each year
- Major disease-causing pathogen: Salmonella/E. coli
Open-Access Testing
> $20 Billion USD markets
- Pharma, biotech, academic labs – (18,000 moderate complexity CLIA labs in the US)
- PCR market – $4.33B USD by 2026
- Genotyping – $11.8B USD
Other open-access markets:
- Water Quality Monitoring – $1.59B USD by 2022
- Agricultural Testing – $6.29B USD by 2022
- Aquaculture Bacterial Testing
Pandemic Prevention
Threat of next outbreak or pandemic is real
- LexaGene technology ideally suited to contain outbreaks
- Need rapid time to results for quarantine decisions
- Test at point-of-need required (hospitals, clinics, institutions)
- Need tests that can be easily deployed
- Require reagents that are easy to manufacture for worldwide coverage
- Current testing methods don’t meet the needs
More Markets
LexaGene’s technology has a wide range of applications across other markets at point-of-need:
- Cruise ships
- Biodefense
- Military bases and aircraft carriers
- Etc.